NCT03186677 - Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 3, 2017

Primary Completion Date

October 10, 2018

Study Completion Date

February 22, 2019

Conditions

Hemophilia B

Interventions

BIOLOGICAL

ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg

ISU304/CB2679d/Dalcinonacog alfa 75\~150 IU/kg by intravenous or subcutaneous

BIOLOGICAL

BeneFIX

BeneFIX 75 IU/kg, intravenous administration

Trial Locations (3)

Eulji University Hospital, Daejeon

Pusan National Univesity Hospital, Pusan

Yonsei University Medical Center, Seoul